Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06869252 · ClinicalTrials.gov registry record · Phase 1

Autologous Adipose Cells Therapy

A Phase 1 study of Hair Thinning and Fine Lines, sponsored by CERM.

Recruiting
Registry status
Phase 1
Development phase
40
Enrollment target
2
Study locations

NCT06869252 is a Phase 1 study of Hair Thinning and Fine Lines that is actively recruiting participants, run by CERM. The registered enrollment target is 40 participants, below the 62-participant average among 10 other Hair Thinning trials with a reported enrollment target (35% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06869252, a Phase 1 study of Hair Thinning and Fine Lines, is actively recruiting participants, sponsored by CERM.

RECRUITING
Registry status
Phase 1
Development phase
40 participants
Enrollment target
2
Study locations

Study Summary

Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell Therapy for skin rejuvenation and hair improvement in human application.

Interventions

  • BIOLOGICAL Autologous Adipose Cells Therapy

Study Locations (2)

Delaware

  • The Centre for Cosmetic Surgery & Medicine, Newark - Lewes
  • The Centre for Cosmetic Surgery & Medicine - Newark

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-01
Est. Completion 2026-02-01
Phase Phase 1

Sponsor

CERM

1 total trials

What the Registry Record Tells You About NCT06869252

The ClinicalTrials.gov registry entry for NCT06869252 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 10 other Hair Thinning trials with a reported enrollment target (35% lower). The listed sponsor is CERM, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Hair Thinning appearing as the primary indexed condition, and to 1 intervention - of which Autologous Adipose Cells Therapy is the first listed.

NCT06869252 reports 2 study locations spanning 1 distinct geographic area - top geographies include Delaware.

Frequently Asked Questions

What is clinical trial NCT06869252 about?

NCT06869252 is a clinical study titled "Autologous Adipose Cells Therapy". Autologous Adipose Cell Therapy is a series of process designated to address the demerits of the traditional autologous fat grafting and dermal fillers, while enhancing the versatility and aesthetic outcomes. In this study, the goal is to evaluate the safety and efficacy of Autologous Adipose cell T...

What is the current status of trial NCT06869252?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-08-01. Estimated completion is 2026-02-01.

What conditions does trial NCT06869252 study?

This clinical trial studies the following conditions: Hair Thinning, Fine Lines, Skin Pigmentation, Skin Elasticity, Hair Loss/Baldness.

What interventions are being tested in trial NCT06869252?

The interventions under investigation include: Autologous Adipose Cells Therapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT06869252?

This trial is sponsored by CERM, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06869252 being conducted?

This trial has 2 study locations across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hair Thinning

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.